(NASDAQ: SKYE) Skye Bioscience's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.8%.
Skye Bioscience's earnings in 2026 is -$55,924,814.On average, 10 Wall Street analysts forecast SKYE's earnings for 2026 to be -$36,366,163, with the lowest SKYE earnings forecast at -$46,777,000, and the highest SKYE earnings forecast at -$22,080,052. On average, 9 Wall Street analysts forecast SKYE's earnings for 2027 to be -$38,729,380, with the lowest SKYE earnings forecast at -$48,152,205, and the highest SKYE earnings forecast at -$29,440,070.
In 2028, SKYE is forecast to generate -$45,622,095 in earnings, with the lowest earnings forecast at -$51,683,678 and the highest earnings forecast at -$39,603,903.